Skip to content
MarketScale
‹ Back to IndustriesHealthcare

AI Adoption in Healthcare is Growing. Healthcare Pros Need To Differentiate Between AI, Automation, and Unfounded Hype.

According to a recent survey from healthcare advisory firm Sage Growth Partners, a staggering 90% of hospitals now have the power of artificial intelligence on their radar, in varying stages of adoption, to revolutionize patient care and streamline operations. AI adoption in healthcare organizations is poised to achieve better, more equitable, and affordable patient outcomes….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

According to a recent survey from healthcare advisory firm Sage Growth Partners, a staggering 90% of hospitals now have the power of artificial intelligence on their radar, in varying stages of adoption, to revolutionize patient care and streamline operations. AI adoption in healthcare organizations is poised to achieve better, more equitable, and affordable patient outcomes. For example, machine learning in medical diagnostics has already shown significant potential to improve the accuracy and efficiency of diagnoses.

Healthcare has increasingly become the ultimate proving ground for AI technology, with applications ranging from predictive analytics to personalized medicine. Experts believe that AI and ML can revolutionize the industry by identifying patterns in complex data, automating repetitive tasks, and enabling more informed decision-making. It’s becoming more and more evident, though, that this technology ecosystem can come with a lot of hype, and that hype can cloud important judgment and understandings around different tech in the artificial intelligence ecosystem. Christina Cussimanio, SVP of Marketing at AGS Health, highlights the growing role of AI adoption in healthcare organizations, emphasizing the distinction between AI and automation while illustrating AI’s potential to transform revenue cycle management.

Christina’s Thoughts

“Did you know more than 80% of healthcare organizations report they’ve already implemented an AI strategy? AI is addressing some of healthcare organizations’ biggest pain points, increasing revenue capture, and helping those early adopters achieve revenue integrity. With that being said, AI and automation are terms that are often used interchangeably.

However, the differences are not as subtle as they appear. While automation’s about setting up bots to follow a set of predefined rules, AI is about setting up cognitive bots to make their own decisions. AI is made up of different technologies that allow the machine to act at the human level of intelligence, a process that requires learning from past experiences and self-correction to make decisions and reach conclusions. A good example of AI is the ability to predict denials by identifying and assessing attributes commonly found in at-risk claims before or prior to submission. You can learn more about the role of AI in RCM operations by reading our white paper, artificial intelligence for RCM, separating hype from reality.”

Article Written by Azam Saghir.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512